![]()
|
|
|
AbD Serotec secures exclusive worldwide license to key diagnostic antibody
07-27-2010
SHARING OPTIONS:
MARTINSRIED, Germany and LONDON—MorphoSys AG reports
that its research and diagnostic antibodies unit AbD Serotec has signed an
exclusive license agreement with UCL Business PLC (UCLB), the technology
development company of University College London. The agreement provides
AbD Serotec with worldwide exclusive access to a potent anti-PTH antibody for commercial
use in research and diagnostic applications. The anti-PTH antibody forms the
basis of an existing relationship between AbD Serotec and a leading diagnostic
company which markets clinical parathyroid hormone assays.
"Our goal is to achieve a market-leading
position in those areas we see as our sweet spots. In this particular case, the
anti-PTH antibody sourced from our relationship with University College London
has already allowed us to forge a first supply agreement with a leading
diagnostic company. We have thus decided to expand this strong position and
take an exclusive license for this product from UCLB," says Dieter Feger, head
of AbD Serotec.
Parathyroid hormone (PTH) is the most important
regulator of calcium levels in the human body. When blood calcium becomes too
low, calcium-sensing receptors in the parathyroid gland are activated and
parathyroid hormone is secreted, thereby mobilizing calcium release from bone
and suppressing calcium loss in urine. Measurement of PTH is important in
determining the cause of excessively high or low calcium levels. High levels
may be due to a parathyroid gland tumor, which is usually benign (primary
hyperparathyroidism) or secondary hyperparathyroidism, which is usually a
result of kidney failure. Low levels may be the result of a failure of the
parathyroid gland. In primary hyperparathyroidism the parathyroid tumor must be
removed.
PTH assays are used as a routine clinical tool to
detect decreases in plasma PTH levels after all diseased tissue has been
excised, even while surgery is taking place. The test allows a more limited
procedure by confirming complete removal of diseased tissue and has reduced the
need for repeated surgery. PTH assays in other conditions provide clinicians
with important information that assists in managing patients with abnormal
calcium levels. Code: E07271002 Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|